Nutriband Inc. Achieves Key Milestone in Development of Abuse-Deterrent Fentanyl Patch

Nutriband Inc. (NASDAQ: NTRB) has announced the completion of commercial-scale manufacturing for AVERSA(TM) Fentanyl in collaboration with Kindeva Drug Delivery, a pivotal advancement towards FDA approval. This development is crucial in the context of the ongoing opioid crisis, highlighting the urgent need for innovative solutions that mitigate the abuse potential of potent opioids like fentanyl while ensuring their therapeutic benefits remain accessible to patients in severe pain.

The AVERSA technology, protected by international patents, represents a significant leap forward in abuse-deterrent formulations. By integrating this technology into fentanyl patches, Nutriband aims to provide a safer alternative for pain management, addressing a global unmet need. The company's recent inclusion in four key indexes, including the Russel Indexes, further underscores its growing profile and the potential impact of its work on public health and safety.

An updated analyst report has raised Nutriband's price target to $15.00, reflecting confidence in the company's execution and the favorable pathway for AVERSA(TM) Fentanyl through clinical trials. This optimism is rooted in the technology's ability to deter abuse, a critical factor in the current regulatory and public health landscape where the balance between access to effective pain management and the prevention of opioid misuse is paramount.

The completion of commercial-scale manufacturing is a testament to Nutriband's commitment to rethinking opioid safety. As the company moves closer to seeking FDA approval for AVERSA(TM) Fentanyl, its efforts could herald a new era in pain management, offering hope for a solution that safeguards against abuse without compromising patient care.